Skip to main content

Gastroparesis EXPEDITE

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures.

Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at monthly study visits.

Mimi S Lin, M.D.
Mimi S Lin, M.D.
Principal investigator
View profile

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Stress Urinary Incontinence PAS001 ProACT

    Post Approval Study of the ProACT™ Adjustable Continence Therapy for Men

    Status: Open to Enrollment

  • Clinical trial

    Chronic Nausea and Vomiting NAVIGATE

    A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System

    Status: Open to Enrollment

  • Clinical trial

    Hepatitis LCAH3141 RE-AHFIRM

    RE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)

    Status: Open to Enrollment

  • Clinical trial

    Kidney Transplant Patients EFC18554 FREXERA

    A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

    Status: Coming Soon

  • Clinical trial

    Microvascular Inflammation in Transplanted Kidney TRANSPIRE

    A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?